河南科技大学学报（医学版）2016，Vol.34Issue(4)：279-280,2.DOI:10.15926/j.cnki.issn1672-688x.2016.04.012
甘精胰岛素联合瑞格列奈治疗2型糖尿病76例
Treatment of 76 Cases of Type 2 Diabetes with Insulin Glargine and Repaglinide
闫景虎 1张春昕2
作者信息
- 1. 洛阳市第二中医院，河南洛阳471003
- 2. 河南科技大学医学技术与工程学院，河南洛阳471003
- 折叠
摘要
Abstract
Objective To observe the effect of type 2 diabetes treated by insulin glargine and repaglinide. Methods 76 patients of type 2 diabetes were randomly divided into the control group and the observation group, and both were given diet and exercise guidance. 38 cases in control group were given 30R human recombinant insulin injection. The initial dose was 0. 4 U·kg-1 every day at 30 min before breakfast and dinner by subcutaneous injection. The patients in observation group were treated by insulin glargine by subcutaneous injection and repaglinide in oral therapy. The initial dose of insulin glargine was 0. 2 U·kg-1 every day before sleep with subcutaneous injection;repaglinide was taken orally 1 mg 3 times per day at 15 min before meal. Fasting plasma glucose(FPG), 2 hours postprandial blood glucose(2hPG), glycosylated hemoglobin ( HbAlc) , and the incidence of hypoglycemia were observed until 3 months. Results The difference of FPG, 2hPG and HbA1c was not statistically significant(P>0. 05) before treatment. However, observation group had a better effect than control group after treatment ( P <0 . 05 ) . The incidence of hypoglycaemia of observation group 7. 9 % (3/38) was less than the control group 28. 9 % (11/38) (P<0 . 05 ) . Conclusion The treatment of type 2 diabetes with insulin glargine and repaglinide was safe and efficient to reduce the FPG, 2hPG, HbAlc and incidence of hypoglycaemia.关键词
2型糖尿病/甘精胰岛素/瑞格列奈Key words
type 2 diabetes/insulin glargine/repaglinide分类
医药卫生引用本文复制引用
闫景虎,张春昕..甘精胰岛素联合瑞格列奈治疗2型糖尿病76例[J].河南科技大学学报（医学版）,2016,34(4):279-280,2.
